Uveitis Market Expected to Experience Accelerated Growth and Market Evolution by 2034 - DelveInsight

DelveInsight's "Uveitis Drugs Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Uveitis, historical and forecasted epidemiology, as well as the Uveitis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for unlocking the CAGR of the Uveitis Drugs Market:
https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Uveitis Market Report

• In January 2026, the U.S. Food and Drug Administration (FDA) cleared Novaliq's Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). The regulatory clearance represents an important milestone in advancing the clinical development of NOV05 for this ophthalmic indication.
• The Uveitis market size in the 7MM was approximately USD 1,468.66 million in 2022 and is projected to increase due to increasing awareness of the disease and the launch of emerging therapies during the forecast period (2024-2034).
• In 2022, the Uveitis market size was highest in the US among the 7MM, accounting for approximately USD 759.03 million, expected to increase by 2034.
• Among EU4 and the UK, Germany accounted for the maximum Uveitis market size, at approximately USD 115.73 million in 2022, while Spain occupied the bottom with nearly USD 90.49 million.
• Japan accounted for the second-largest Uveitis drugs market among the 7MM, at approximately USD 196.62 million in 2022, expected to increase during the forecast period (2024-2034).
• Corticosteroids captured the second-highest market share in the 7MM at USD 344.78 million in 2022, of which YUTIQ/ILUVIEN accounted for USD 32.34 million and other corticosteroids accounted for USD 312.44 million.
• YUTIQ/ILUVIEN, a sterile nonbioerodible intravitreal implant containing 0.18 mg fluocinolone acetonide, was approved by the US FDA in October 2018 and launched commercially in February 2019 for chronic noninfectious uveitis affecting the posterior segment of the eye.
• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM, with around 378,281 cases in the US.
• The US contributed the largest Uveitis diagnosed prevalent population, acquiring ~37.5% of the 7MM in 2022, while Spain accounted for the least, at around ~7%.
• Emerging therapies TRS01 (Tarsier Pharma), licaminlimab/OCS-02 (Oculis Pharma), and vamikibart/RO7200220 (RG6179) (Roche) can potentially create a positive shift in the uveitis market during the forecast period.
• If approved, Tarsier Pharma's TRS01 would be the first nonsteroidal eye drops to treat noninfectious anterior uveitis; it is expected to enter the US market by 2026 and is projected to generate revenue of USD 2.91 million in its launch year.
• Roche's vamikibart (RG6179), a recombinant humanized immunoglobulin suppressing IL-6 signaling, acts against uveitic macular edema and is expected to enter the US market by 2026, with a projected slow-medium uptake in EU4 and the UK starting in 2027.
• OCS-02 (licaminlimab), a single-chain antibody fragment with a dual anti-inflammatory and anti-necrosis mechanism, addresses the need for a steroid-sparing topical biologic without associated systemic risks.
• Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.
• Key Uveitis Therapies: XIPERE, YUTIQ/ILUVIEN, HUMIRA, OZURDEX, RETISERT, DUREZOL, TRS01, OCS-02 (licaminlimab), vamikibart (RG6179), and others.
• No biologics have been specifically approved for uveitis, though adalimumab (HUMIRA) is approved for treating noninfectious uveitis (NIU), and remains the lone approved product in this category, enjoying a major market share of biologics.

Uveitis Overview

Uveitis is a sight-threatening inflammatory disease affecting the middle uveal layer of the eye, occurring when the immune system fights an infection affecting the uveal tract (composed of the iris, choroid, and ciliary body) and adjacent structures. Uveitis is one of the leading causes of visual morbidity, with over one-third of patients having a visual impairment and accounting for about 10-15% of blindness cases worldwide. Anterior uveitis is the most prevalent form, accounting for approximately 50% of cases, while posterior uveitis is the least common. Uveitis can occur at any age, but peak incidence is between 20 and 59, with females under age 50 appearing most affected.

To know in detail about the Uveitis market outlook, drug uptake, treatment scenario, and epidemiology trends, refer to the full report:
https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Uveitis Epidemiology

As the market is derived using a patient-based model, the epidemiology chapter provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, type-specific diagnosed prevalent cases, diagnosed prevalent cases by anatomical location, and etiology-specific diagnosed prevalent cases in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

Key Findings from Uveitis Epidemiological Analysis and Forecast

• In 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM, with around 378,281 cases in the US.
• The US contributed the largest diagnosed prevalent population, at ~37.5% of the 7MM in 2022, while Spain accounted for the least, at ~7%.
• In the US, noninfectious uveitis (NIU) cases (nearly 344,587 in 2022) outnumbered infectious uveitis (IU) cases (around 33,695), with both expected to rise during the forecast period.
• In EU4 and the UK, anterior uveitis had the highest cases based on anatomical location (approximately 203,439 in 2022), followed by 84,154 posterior uveitis, 81,773 pan uveitis, and 46,485 intermediate uveitis cases.
• Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis in 2022, including 8,039 HLA-B27-associated, 17,315 sarcoidosis, 9,894 Behçet's disease, 8,658 Vogt-Koyanagi-Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 other cases.

Uveitis Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of Uveitis
• Type-specific Diagnosed Prevalent Cases of Uveitis
• Diagnosed Prevalent Cases of Uveitis by Anatomical Location
• Etiology-specific Diagnosed Prevalent Cases of Uveitis

Uveitis Drugs Uptake and Pipeline Development Activities

The drugs market chapter segment encloses a detailed analysis of uveitis-marketed drugs and late-stage (Phase III and Phase II) pipeline drugs, covering clinical trials details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each drug, and the latest news and press releases.
The drugs uptake section focuses on the uptake rate of potential Uveitis drugs expected to be launched during 2020-2034.

Uveitis Therapies and Key Companies

• XIPERE: Clearside Biomedical/Bausch + Lomb
• YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences
• HUMIRA (adalimumab): AbbVie
• OZURDEX: Allergan
• RETISERT: Bausch + Lomb
• TRS01: Tarsier Pharma
• OCS-02 (licaminlimab): Oculis Pharma
• Vamikibart (RO7200220/RG6179): Roche/Eleven Biotherapeutics

Discover more about therapies set to shape the Uveitis market landscape:
https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Uveitis Market Drivers

• Rising uveitis prevalence in the US.
• Advancements in disease nomenclature, clinical trials, drug delivery systems, multimodality diagnostic imaging, laboratory testing, and ocular immunology research.
• Launch of emerging therapies such as TRS01, licaminlimab (OCS-02), and vamikibart (RG6179).

Uveitis Market Barriers

• Lack of evidence supporting many interventions and absence of proper consensus guidelines.
• No curative therapy currently exists, and long-term immunosuppressant use is associated with severe adverse effects.

Scope of the Uveitis Market Report

• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Coverage: 7MM
• Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.
• Key Uveitis Therapies: XIPERE, YUTIQ/ILUVIEN, HUMIRA, OZURDEX, RETISERT, DUREZOL, TRS01, OCS-02 (licaminlimab), vamikibart (RG6179), and others.
• Uveitis Therapeutic Assessment: Current marketed and emerging therapies.
• Uveitis Market Dynamics: Market drivers and market barriers.
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis.
• Uveitis Unmet Needs, KOL Views, Market Access and Reimbursement.

Table of Contents

• Uveitis Market Key Insights
• Uveitis Market Report Introduction
• Uveitis Market Overview
• Uveitis Epidemiology and Market Forecast Methodology
• Uveitis Market Executive Summary
• Uveitis Market Key Events
• Uveitis Disease Background and Overview
• Uveitis Patient Journey
• Uveitis Epidemiology and Patient Population
• Uveitis Marketed Drugs
• Uveitis Emerging Drugs
• Uveitis Market Analysis (7MM)
• Uveitis Key Opinion Leaders (KOL) Views
• Uveitis SWOT Analysis
• Uveitis Unmet Needs
• Uveitis Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.